Recently, the C–C chemokine receptor 4 (CCR4) targeting glyco-engineered antibody mogamulizumab has been approved in Japan for use in patients with relapsed and refractory CCR4-positive adult T cell leukemia/lymphoma (ATL) (Beck and Reichert, 2012). The gene discussed is CCR4; the disease is lymphoma.